XSHG
600529
Market cap1.79bUSD
Oct 09, Last price
18.28CNY
1D
0.99%
1Q
0.66%
Jan 2017
68.48%
IPO
511.37%
Name
Shandong Pharmaceutical Glass Co.
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Shandong Pharmaceutical Glass Co., Ltd (SPG), headquartered in Zibo, China, is a manufacturer and supplier specializing in pharmaceutical glass packaging and related butyl rubber products. The company's extensive product portfolio encompasses a diverse range of glass packaging solutions. This includes essential items like molded injection vials, tubular glass vials, and ampoules, alongside various borosilicate glass products. SPG also supplies specialized containers such as amber, cobalt blue, and green bottles, as well as clear cosmetic and food-grade bottles. Beyond glass, SPG produces critical components like butyl rubber stoppers (including Teflon-coated variants), various plastic and aluminum caps, and dropper caps. They also provide prefilled syringes and plastic bottles. These offerings primarily cater to the pharmaceutical, food, and cosmetic packaging sectors. While maintaining a significant presence in the domestic Chinese market, SPG also extends its reach globally, exporting to numerous international markets such as Europe, the United States, Russia, Japan, Korea, and Southeast Asia. Established in 1970, the company boasts a long history in the industry.
Key people
Wen Chai
Chairman of the Board
Yizhao Song
Finance Director · since 2013
Yong Gang Hu
General Manager, Director · since 2003
Deputy General Manager, Director · since 2008
Zai Yi Zhou
Deputy General Manager, Director · since 2003
Haibao Zhao
Secretary of the Board · since 2010
Gang Chen
Director · since 2013
Xi Wang
Director · since 2013
Independent Director · since 2010
Independent Director · since 2009
Zhongli Zhu
Independent Director · since 2009
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||